Project Oncology®
Showcasing major breakthroughs in cancer care from worldwide clinical trials, Project Oncology® educates and assists the healthcare professionals who dedicate their lives to helping patients fight cancer.
Here you’ll find leading oncologists discuss and share essential cancer care strategies for all different types of cancer. And as worldwide clinical trials continue to explore new screening tests and discover novel treatment options, you can rest assured that you’ll always catch the latest in cancer research with Project Oncology®.
Episodes 1-15 of 326
Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Project Oncology®Real-World Cases in Pediatric Low-Grade Glioma: Exploring Targeted Therapies
Immunotherapy Advances in Early-Stage Upper GI Cancers: Key Trial Insights
Project Oncology®Immunotherapy Advances in Early-Stage Upper GI Cancers: Key Trial Insights
Stories in PNH: Case Experiences from the Clinic
Project Oncology®Stories in PNH: Case Experiences from the Clinic
Understanding the Role of the Alternate Complement Pathway in PNH
Project Oncology®Understanding the Role of the Alternate Complement Pathway in PNH
- advertisement
Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Recognizing the Burden of Paroxysmal Nocturnal Hemoglobinuria
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®Examining the Treatment Paradigm for Paroxysmal Nocturnal Hemoglobinuria
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®Managing PNH Patients: Addressing the Unmet Needs
- advertisement
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures





























































